MiPet Easecto



This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR) for MiPet Easecto.It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use MiPet Easecto.

For practical information about using MiPet Easecto, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.

This EPAR was last updated on 15/05/2019

Authorisation details

Product details
MiPet Easecto
Agency product number
Active substance
International non-proprietary name (INN) or common name
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Zoetis Belgium SA
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Rue Laid Burniat 1
1348 Louvain-la-Neuve

Product information

21/03/2019 MiPet Easecto - EMEA/V/C/004732 - WS/1553

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Ectoparasiticides for systemic use

Therapeutic indication

For the treatment of tick infestations (Dermacentor reticulatus, Ixodes hexagonus,Ixodes ricinus and Rhipicephalus sanguineus). The veterinary medicinal product has immediate and persistent tick killing activity for at least 5 weeks.

For the treatment of flea infestations (Ctenocephalides felis and Ctenocephalides canis). The veterinary medicinal product has immediate and persistent flea killing activity against new infestations for at least 5 weeks. The veterinary medicinal product can be used as part of a treatment strategy for the control of Flea Allergy Dermatitis (FAD).

For the treatment of sarcoptic mange (Sarcoptes scabiei).

For the treatment of ear mite infestations (Otodectes cynotis).

For the treatment of demodicosis (Demodex canis).

Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.

Assessment history

Related content

How useful was this page?

Add your rating
1 rating
1 rating